App-Based Tracking Shows Cannabis May Temporarily Reduce Autism-Related Symptoms by 73%

Among 111 self-identified autistic adults tracking cannabis use through the Strainprint app, symptom severity ratings dropped by an average of 73% from before to after cannabis use. More severe baseline symptoms were associated with greater reductions. Higher doses predicted greater improvements in repetitive behaviors, mental control, and negative affect.

Retrospective analysis of anonymized archival data from the Strainprint app. 111 self-identified autistic adults tracked symptom changes before and after cannabis use across four domains: sensory sensitivity, repetitive behaviors, mental control, and negative affect.

Effective pharmacological treatments for core autism symptoms remain limited. This is one of the first studies to measure perceived acute effects of cannabis on autism-specific symptoms in adults, though the self-report design means the findings are preliminary.

Cannabis use is common in the autistic community, but research has lagged behind practice. While these self-reported improvements are striking, they reflect perceived acute effects rather than measured clinical outcomes, and placebo effects cannot be ruled out.

Self-reported data from an app without a control group. Self-identified autism without clinical confirmation. No way to account for expectancy or placebo effects. The 73% improvement figure may reflect response bias, as users who find cannabis helpful are more likely to continue tracking.